LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
Hatchtech mechanism of action data and safety study published
Specialty pharmaceutical company Hatchtech Pte Ltd has published data describing the mechanism of action of the active ingredient (Ha44) in its lead product DeOvo™, a single application topical treatment for head lice.

The research data, published in the journal PLOS ONE describes the ability of Ha44 to fatally disrupt all stages of the life cycle of the model organism Drosophila melanogaster, from eggs to adult flies. Ha44, a small heterocyclic organic molecule, is able to chelate heavy metal ions including zinc, iron and copper and thereby disrupt metal dependent targets within the insect that require these ions for normal function.

”This research conducted under an ARC Linkage Grant in conjunction with The University of Melbourne is consistent with the spectrum of activity of Ha44 that we have observed against head lice in the laboratory and in clinical studies. It demonstrates all stages from eggs to adults are susceptible to the compound with a single application,” said Dr Vern Bowles, Hatchtech’s Chief Scientific Officer. ”Furthermore the results indicate that Ha44 is acting on several targets within the insect which suggests that target site resistance is unlikely to evolve.”

The company also announced that it had successfully completed a Thorough QT (TQT) study, a clinical safety assessment required by US and European regulators for nearly all new molecular entities. Dr Lewis Schulz, Hatchtech’s chief operating officer said, “We are very pleased with the results of the TQT study which provide further data supporting the safety profile of DeOvo."

Click here for the complete issue.


Credits to: American Chemical Society

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy